New TB vaccine candidate MTBVAC enters Mid-Stage human trial
NCT ID NCT06997367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a new tuberculosis vaccine called MTBVAC (BBV169) in 164 healthy adolescents and adults. Some participants get the new vaccine, others get the standard BCG vaccine. The study checks how safe the vaccine is and how well it triggers an immune response, aiming to find a better TB vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTBVAC (BBV169) vaccine
What this could lead to
If successful, this could lead to a more effective tuberculosis vaccine than the current BCG, potentially reducing TB cases worldwide.
What could go wrong
This is a mid-stage trial with only 164 participants, so results may not apply broadly. The vaccine is still experimental and may not prove safer or more effective than BCG.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS (TB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIIMS-Delhi
New Delhi, 110029, India
-
Guru Teg Bahadur Hospital
Delhi, 11009, India